INSPIRED BY LOVE!
POWERED BY RESEARCH DATA SCIENCE DISCOVERY

Developing treatments for tomorrow,
to improve lives today.

Developing treatment for tomorrow,
to improve lives today.

At Xinvento (zin-ven-toh), our aim is to positively impact the lives of those living with congenital hyperinsulinism.

Our research and development will provide a credible alternative treatment for congenital hyperinsulinism, improving accessibility to modern medicine for patients.

By alleviating the difficulties associated with the disease, we will enhance the quality of life for both patients and carers, freeing up time for families to focus on the more enjoyable parts of life.

What is Congenital Hyperinsulinism?

Congenital hyperinsulinism (often referred to as CHI) is the most frequent cause of severe, random, and persistent hypoglycemia in newborns and children.

Hypoglycemia (a ‘hypo’) results from an over-secretion of insulin, which causes blood sugar levels to fall dangerously low. Without proper and immediate treatment to prevent hypos, the child may suffer seizures, coma, permanent brain damage, or even death.

Why is Congenital Hyperinsulinism our focus?

It’s rare.

CHI is classed as a rare disease; in that it affects a small percentage of the population.

Such rare diseases also become orphan diseases, so-called because they are not fully adopted by the pharmaceutical industry.

With such rarity comes the scarcity of medical support, including resources for discovering new treatments for it.

Xinvento wants to change this for CHI patients.

It’s lifelong.

Currently, being born with CHI means living life under constant threat.

The lifelong impact can result in developmental delays, epilepsy, cerebral palsy, and other neurological damage. Daily interventions are required, including many needle pricks, often 24/7 nutritional needs, and regular hospital visits.

For caregivers, it takes the enormous responsibility of raising a child to new extremes. It’s an exhausting battle, and it’s every single day.

It’s time.

The most common current treatment for congenital hyperinsulinism was developed 50 years ago for another disease, resulting in major downsides.

Despite daily medical interventions, hypos still occur.

We need new solutions to lower the incidence and severity of hypos, and we need them now.

That’s where Xinvento comes in…

Our Story

The origins of Xinvento…
Our endeavor began after Claudine van der Sande (CEO and Founder) gave birth to her son.

Soon after he was born, Claudine and her husband noticed he seemed to be constantly crying, even more than would be expected for a newborn baby. They knew he was unwell and in pain, but despite numerous visits to the doctor, no one could ascertain the cause of his discomfort. Undeterred, they pursued further medical evaluation, and eventually their son was diagnosed with congenital hyperinsulinism.

Despite daily intervention and weekly hospital visits, Claudine’s son continued to experience extremely low blood sugar, suffered regular hypoglycemic episodes, and remained at acute risk of seizures.

With no respite in sight and limited drug options, her motherly instinct kicked in, and she vowed to do everything in her power to secure the best care and treatment for her son. Claudine then set out on a mission to better understand congenital hyperinsulinism, the particular type her son had, what this diagnosis would mean for the entirety of his life, and the impact on their family.

The journey begins…
With her extensive background in the pharmaceutical industry, Claudine soon realized that she was perfectly suited to do something constructive about it and not just for her son but for everyone suffering from this disease.

So, at the beginning of 2021, Claudine began conducting extensive research, reviewing the available literature, and meeting with medical and scientific experts.

To further her understanding, she reached out for help from individuals who had first-hand experience in finding new treatments for rare diseases. After hearing her story, each promptly joined her mission, and a team of experienced professionals was subsequently assembled.

Xinvento is launched…
By the end of 2021, Xinvento was officially launched. The company now serves as the platform for researching and developing a more effective treatment for congenital hyperinsulinism and for other illnesses caused by hyperinsulinism.

Through Xinvento, Claudine and the team will not only be able to save her son and provide him with a better quality of life, but also give hope to the countless lives around the world adversely impacted by congenital hyperinsulinism.